Trial Profile
Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 19 Dec 2015 Primary endpoint has been met. (determine a profound neuromuscular blockade reversal on ideal body weight), as published in the Anaesthesia
- 19 Dec 2015 Results published in the Anaesthesia
- 15 Sep 2015 New trial record